Quarterly report pursuant to Section 13 or 15(d)

Subsequent Events (Details)

v3.22.1
Subsequent Events (Details) - Subsequent event - R-Bridge Financing
$ / shares in Units, $ in Millions
1 Months Ended
Apr. 30, 2022
USD ($)
area
$ / shares
shares
Royalty Based Loan Agreement  
Subsequent Event  
Upfront payment $ 15.0
Commercialization milestone payments $ 10.0
Debt instrument, first tranche call from closing of the deal, time period 15 days
Number of firm's core areas | area 3
Warrants to purchase shares of common stock | shares 5,000,000
Warrants term 3 years
Exercise price | $ / shares $ 0.82
Royalty Based Loan Agreement - First Tranche  
Subsequent Event  
Proceeds from royalty-based loan agreement $ 15.0
China | Royalty Based Loan Agreement  
Subsequent Event  
Milestone payment upon first commercial sale in China $ 15.0
Jiangsu Nhwa Pharmaceutical Co Ltd | China  
Subsequent Event  
Net revenue interest in U.S. net sales (as a percent) 4.00%
Cap of U.S. revenue interest if Chinese approval occurs by year-end 2023 $ 10.0
Net revenue interest in U.S. net sales if approval target is not reached (as a percent) 7.00%
Milestone payment upon regulatory approval in China $ 3.0